

1  
2  
3  
4  
5  
6  
7  
8 **Quantitative mRNA Analysis of Eight Bovine 5-HT**  
9 **Receptor Subtypes in Brain, Abomasum, and**  
10 **Intestine by Real-Time RT-PCR**  
11  
12  
13

14 **Martin Reist,<sup>1,2</sup> Michael W. Pfaffl,<sup>3</sup> Claudine Morel,<sup>2</sup> Mireille Meylan,<sup>1</sup>**  
15 **Gabriela Hirsbrunner,<sup>1</sup> Jürg W. Blum,<sup>2</sup> and Adrian Steiner<sup>1,\*</sup>**  
16

17 <sup>1</sup>Department of Clinical Veterinary Medicine, Clinic for Ruminants, and  
18 <sup>2</sup>Division of Animal Nutrition and Physiology, Institute of Animal Genetics,  
19 Nutrition and Housing, Faculty of Veterinary Medicine,  
20 University of Berne, Berne, Switzerland  
21 <sup>3</sup>Institute of Physiology, Technical University of Munich,  
22 Freising-Weihenstephan, Germany  
23  
24  
25  
26

27 **ABSTRACT**

28  
29 Serotonergic pathways are involved in economically important bovine gastrointestinal  
30 (GI) motility disorders such as displaced abomasum and cecal dilatation/dislocation.  
31 The existing research tools to investigate the role of serotonergic pathways in such  
32 disorders in ruminants comprise functional pharmacological methods, e.g., in vitro  
33 contractility studies in tissue baths, and electromyographical recordings in vivo. How-  
34 ever, no tools for quantification of bovine serotonin receptor [5-hydroxytryptamine  
35 receptor (5-HTR)] expression were available so far. This study aimed to develop  
36 real-time RT-PCR assays for quantitative mRNA analysis of bovine 5-HTR subtypes.  
37 Because the bovine 5-HTR coding sequences (CDSs) were completely unknown,  
38 multiple species (human, mouse, and rat) alignment of complete CDS was used for  
39 primer design in highly homologous regions. LightCycler real-time RT-PCR  
40

41 

---

\*Correspondence: Adrian Steiner, Department of Clinical Veterinary Medicine, Clinic for  
42 Ruminants, Faculty of Veterinary Medicine, University of Berne, CH-3012 Berne, Switzerland;  
43 Fax: +41-31-631-2631; E-mail: adrian.steiner@knp.unibe.ch.  
44

assays (partial CDS) for the following bovine 5-HTR subtypes were developed and validated: 5-HTR<sub>1A</sub>, 5-HTR<sub>1B</sub>, 5-HTR<sub>1D</sub>, 5-HTR<sub>1F</sub>, 5-HTR<sub>2A</sub>, 5-HTR<sub>2B</sub>, 5-HTR<sub>2C</sub>, and 5-HTR<sub>4</sub>. Intra- and inter-assay coefficients of variation (CV) for the eight established assays were small, ranging from 0.49% to 2.46%. As a first physiological application, 5-HTR mRNA expression levels were measured in brain, abomasum, and intestine of 10 healthy, lactating dairy cows. The 5-HTR expression was quantified by normalization to the housekeeping gene glyceraldehyde-phosphate-dehydrogenase (GAPDH). The 5-HTR subtype expression levels ranged from 0.001% (5-HTR<sub>2C</sub> in intestine) to 1% 5-HTR/GAPDH (5-HTR<sub>1B</sub> and 5-HTR<sub>4</sub> in intestine). There were high variations of 5-HTR subtype mRNA expression within tissues across receptor subtypes and within receptor subtypes across tissues. In conclusion, accurate real-time RT-PCR assays for quantitative analysis of bovine 5-HTR subtype gene expression were developed and validated.

*Key Words:* Serotonin receptor (5-HTR); Bovine; Quantitative mRNA analysis; Real-time RT-PCR.

## INTRODUCTION

Serotonin [5-hydroxytryptamine (5-HT)] is involved in a wide range of physiological functions as well as in a wide range of pathological states. Serotonin was first discovered as an important brain neurotransmitter that has effects on complex behaviors such as mood and appetite and that is relevant to depression, migraine, and several neuropsychiatric illnesses (1,2). Hence, 5-HT receptors (5-HTR) are best described in the central nervous system (3). However, 5-HT also plays important roles in other tissues. About 95% of 5-HT is found in the gastrointestinal (GI) tract, especially in enterochromaffin cells, but also in serotonergic neurons (4). The 5-HT released by mechanical or vagal stimulation binds to 5-HTR and then acts locally to regulate GI function such as motility of the GI tract, which is either enhanced or inhibited via multiple 5-HTR subtypes. The 5-HTRs have been found along most segments of the GI tract of mammals (4). Although 5-HTRs have been highly conserved throughout evolution, as evidenced by molecular cloning (5), there seem to exist important differences among species in the function of individual receptor types (6,7). Fourteen different 5-HTR subtypes are known so far; they consist of at least two distinct types of molecular structures: G protein-coupled receptors (5-HTR<sub>1</sub>, 5-HTR<sub>2</sub>, 5-HTR<sub>4</sub>, 5-HTR<sub>5</sub>, 5-HTR<sub>6</sub>, 5-HTR<sub>7</sub>) and ligand-gated ion channels (5-HTR<sub>3</sub>) (5). The G protein-coupled 5-HTRs regulate two major intracellular second messenger pathways, adenylate cyclase and phospholipase C (8). Receptors of the 5-HTR<sub>1</sub> family are negatively coupled to adenylate cyclase activation, whereas 5-HTR<sub>2</sub> are positively coupled to phospholipase C, and 5-HTR<sub>4</sub> positively coupled to adenylate cyclase activation. Thus, different cascades of intracellular events are activated via second messengers (cyclic nucleotides after activation of adenylate cyclase, or hydrolysis products of phosphoinositol in the case of phospholipase C, respectively) after interaction of serotonin with receptors (1,8,9).

In ruminants, disorders of GI motility such as displaced abomasum and cecal dilatation/dislocation are frequent and economically important (10,11). However, the serotonergic pathways were predominantly studied in humans and rodents. The 5-HT was shown to be involved in the initiation and regulation of the myoelectric migrating complex (MMC), in the peristaltic reflex, in the regulation of stomach, small intestine and colon motility, as well as in intestinal secretion (4,9,12–23). The mechanisms of action of

95 5-HT in the digestive tract are not completely understood and the role of 5-HTR subtypes  
96 in the regulation of GI motility differs among species and locations along the GI tract  
97 (9,24,25).

98 In ruminants, 5-HT has been shown to be involved in the regulation of forestomach,  
99 abomasal, and intestinal motility (21,26–30). Most of the research available on the effects  
100 of 5-HT on GI motility in ruminants has been conducted in sheep. In this species, 5-HT  
101 reduces forestomach motility and increases the rumen wall tone (26,29,30). Similar results  
102 have been observed in goats (31). In another study in sheep, 5-HTR<sub>1A</sub>, 5-HTR<sub>2</sub>, 5-HTR<sub>3</sub>,  
103 and 5-HTR<sub>4</sub> are reported to be involved in the regulation of forestomach motility  
104 occasionally recorded concomitantly to duodenal phase III activity (21,32). Furthermore,  
105 5-HT is also implicated in the regulation of MMC patterns in the abomasum and proximal  
106 small intestine (17,19–21,27,33), but little is known about the role of the respective 5-HTR  
107 subtypes involved in motility control in ruminants.

108 The literature on the role of 5-HT in the regulation of motility in the bovine GI tract is  
109 almost inexistent, and, with the exception of one publication stating that 5-HT containing  
110 cells are more numerous in the bovine small intestine than in the abomasum or in the large  
111 intestine (34), we are not aware of reports on the distribution and physiological role of the  
112 different 5-HTR subtypes in the bovine digestive tract.

113 Quantitative real-time RT-PCR analysis is a useful tool to measure specific receptor  
114 gene expression and to differentiate between various receptor subtypes or splice variants in  
115 disease models (35–38). While the human, rat, and mouse complete coding sequences  
116 (CDS) of the 14 different 5-HTR subtypes have been determined and published, the bovine  
117 5-HTR nucleotide sequences were completely unknown so far. However, quantitative  
118 mRNA analysis of bovine 5-HTR subtypes would be an important tool to study 5-HTR-  
119 mediated GI diseases in farm animals and could complete the present panel of research  
120 tools such as functional pharmacological methods, e.g., in vitro contractility studies in  
121 tissue baths, and electromyographical recordings in vivo.

122 Based on such observations, we aimed to develop LightCycler real-time RT-PCR  
123 protocols for quantitative analysis of bovine 5-HTR subtype mRNA and to compare the  
124 expression levels of bovine 5-HTRs between tissues from brain, abomasum, and intestine.  
125 We were especially interested in 5-HTR<sub>1</sub>, 5-HTR<sub>2</sub>, and 5-HTR<sub>4</sub> receptor subtypes, as these  
126 are expected to play most likely an important role in GI motility (4,17,21).

127

128

129

130

## 131 MATERIAL AND METHODS

132

### 133 Tissue Samples, Total RNA Preparation, and cDNA Synthesis

134

135 Tissue samples of brain [cortex (lobus piriformis), thalamus, and hypothalamus],  
136 abomasum [fundus, corpus, antrum pylori], and intestine [ileum, caecum, proximal loop of  
137 the ascending colon (PLAC), and spiral colon] of 10 healthy lactating cows culled in the  
138 slaughterhouse of Berne, Switzerland, were taken within 20 min of stunning. Abomasum  
139 and intestine tissue were dissected in the slaughterhouse. The heads of the cows were  
140 transferred to the Faculty of Veterinary Medicine, University of Berne, Switzerland  
141 (10 min drive), and were dissected in the high-security facilities of the Institute of Virology  
142 and the Institute of Neurology. The dissected tissues were rinsed with ice-cold PBS

142 (pH 7.4), kept in 3 parts of RNeasy<sup>®</sup> (Ambion Inc., Austin, TX) at 4°C for 24 h, and  
143 then stored at -20°C until assayed within 4 weeks. For RNA preparation, 200 mg of each  
144 tissue were homogenized with an Ultra-Turrax<sup>®</sup> T 8 homogenizer (IKA Werke GmbH &  
145 Co. KG, Staufen, Germany) in Sarstedt tubes using 2 mL TriFast Isolation Reagent  
146 (PeqLab Biotechnologie GmbH, Erlangen, Germany) and incubated for 5 min at room  
147 temperature (rt). After addition of 0.4 mL chloroform and vortexing for 15 s, the tissue  
148 homogenate was incubated for 10 min at rt. After centrifugation for 15 min at 12,000g and  
149 4°C, the RNA (being in the upper aqueous phase) was carefully pipetted into 1.5 mL  
150 Eppendorf tubes, precipitated by adding 0.5 mL 2-propanol, and centrifuged for 10 min  
151 at 12,000g at 4°C. The supernatant was decanted and the RNA pellets were washed twice  
152 with 75% ethanol followed at each time by centrifugation at 9200g for 8 min at 4°C. The  
153 supernatant was decanted completely and after the second washing step the pellets were  
154 dried for 10 min at 37°C. The pellets were diluted in 30 µL RNase-free water.

155 In order to quantify the extracted total RNA, the optical density of the RNA stock  
156 solution was determined at 260 nm. Additionally, the optical density of the OD<sub>260nm</sub>/  
157 OD<sub>280nm</sub> (nucleic acid/protein) absorption ratio was measured which lay in an optimum  
158 range between 1.8 and 2.0. The stock solution was diluted into a working solution of  
159 100 ng/µL by adding RNase-free water and the RNA density was again optically determined  
160 in triplicates at 260 nm.

161 Synthesis of first strand complementary DNA (cDNA) was performed with 200 units  
162 of reverse transcriptase (MMLV-RT, Promega, Madison, WI) and 100 pmol random  
163 hexamer primers (MBI Fermentas, St. Leon-Rot, Germany). The final concentration of  
164 reversely transcribed total RNA (cDNA) was 25 ng/µL.

165 For further analysis, in each individual animal the cDNA was pooled in equal amounts  
166 as described below:

- 167
- 168 • Brain pool (CNS): cortex (lobus piriformis), hypothalamus, thalamus.
  - 169 • Abomasum pool: fundus, corpus, antrum pylori.
  - 170 • Intestine pool: ileum, caecum, PLAC, spiral colon.
- 171

### 172 Multiple Species Primer Design

173

174

175 The primers used for the production of recDNA were derived either from human, rat,  
176 or mouse sequences. Primers were designed to produce an amplification product which  
177 spanned at least two exons in the highly conserved coding region of the appropriate CDS  
178 of multiple species. Therefore, a multiple CDS alignment (clusteral alignment in  
179 HUSAR<sup>®</sup> software) of the available mRNAs was done at DKFZ (<http://genome.dkfzheidelberg.de/biounit/>). Primer design and optimization was done in the high  
180 homology regions of the multiple alignment with regard to primer dimer formation,  
181 self-priming formation and primer melting temperature (HUSAR<sup>®</sup> software at DKFZ).  
182 Housekeeping gene oligonucleotide sequences were taken from earlier publications  
183 (38,39). The sequences of PCR forward (f) and reverse (r) primers, position of the  
184 primers in the CDSs, PCR product length, and National Center for Biotechnology  
185 Information (NCBI) accession numbers of the published nucleic acid sequences  
186 (<http://www.ncbi.nlm.nih.gov/Entrez/index.html>) used for primer design are summar-  
187 ized in Table 1.

188

**Table 1.** Sequences of PCR primers, position of the forward (f) and reverse (r) primers in CDS, PCR product lengths, and NCBI accession numbers (ac. no.) of published nucleic acid sequences used for primer design.

Primer	Sequence (5'-3')	CDS	Length	NCBI ac. no. <sup>a</sup>
5-HTR <sub>1A</sub> f	TCAGGTACCAAGTGATCACCTCT	98-120	211	XM_003692 (human)
5-HTR <sub>1A</sub> r	GTCCACTTGTGAGCACCTG	308-289		
5-HTR <sub>1B</sub> f	TGCTCCTCATCGCCCTCTATG	665-685	259	XM_004117 (human)
5-HTR <sub>1B</sub> r	CTAGCGGCCATGAGTTTCTTCT	923-901		
5-HTR <sub>1D</sub> f	CCTCCAACAGATCCCTGAATG	44-64	359	NM_000864 (human)
5-HTR <sub>1D</sub> r	CAGAGCAATGACACAGAGATGCA	402-380		
5-HTR <sub>1F-2</sub> f	TGTGAGAGAGAGCTGGATTATGG	252-272	248	NM_000866 (human)
5-HTR <sub>1F-1</sub> r	TAGTTCCTTGGTGCCTCCAGAA	499-478		
5-HTR <sub>2A-2</sub> f	AGCTGCAGAATGCCACCAACTAT	311-333	322	NM_000621 (human)
5-HTR <sub>2A-3</sub> r	GGTATTGGCATGGATATACCTAC	632-610		
5-HTR <sub>2B-2</sub> f	AAACAAGCCACCTCAACGCCT	756-776	411	XM_048724 (human)
5-HTR <sub>2B-1</sub> r	TCCCGAAATGCTTATTGAAGAG	1166-1144		
5-HTR <sub>2C-2</sub> f	TTCTTAATGTCCCTAGCCATTGC	280-302	251	NM_000868 (human)
5-HTR <sub>2C-3</sub> r	GCAATCTTCATGATGGCCTTAGT	530-508		
5-HTR <sub>4-2</sub> f	ATGGACAAAATTGATGCTAATGTGA	1-25	220	XM_052171 (human)
5-HTR <sub>4-2</sub> r	TCACCAGCACCGAAACCAGCA	220-200		
GAPDH-2 f <sup>b</sup>	GTCCTTCACTACCATGGAGAAGG	265-286	197	U85042 (bovine)
GAPDH-2 r <sup>b</sup>	TCATGGATGACCTTGGCCAG	461-442		
UbC-3 f <sup>c</sup>	AGATCCAGGATAAGGAAGGCAT	86-107	654	Z18245 (bovine)
UbC-3 r <sup>c</sup>	GGTCCACCTCCAGGGTGAT	739-721		
18S-2 f <sup>d</sup>	GAGAAACGGCTACCACATCCAA	55-76	337	AF176811 (bovine)
18S-2 r <sup>d</sup>	GACACTCAGCTAAGAGCATCGA	391-370		

<sup>a</sup>Web address: <http://www.ncbi.nlm.nih.gov/entrez/index.html>.<sup>b</sup>GAPDH: glyceraldehyde-phosphate-dehydrogenase.<sup>c</sup>UbC: ubiquitin.<sup>d</sup>18S: 18S ribosomal RNA gene.189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235

### Quantification by Real-Time RT-PCR

236

237

238 Polymerase chain reaction was performed in the LightCycler<sup>®</sup> (Roche Diagnostics,  
239 F. Hoffmann-La Roche Ltd, Basel, Switzerland) with 25 ng reversely transcribed total  
240 RNA (25 ng/ $\mu$ L). A master-mix of the following reaction components was prepared to the  
241 indicated end concentration: 6.4  $\mu$ L water, 1.2  $\mu$ L MgCl<sub>2</sub> (4 mM), 0.2  $\mu$ L forward primer  
242 (4 pM), 0.2  $\mu$ L reverse primer (4 pM) and 1.0  $\mu$ L LightCycler Fast Start DNA Master  
243 SYBR Green I<sup>®</sup> (Roche Diagnostics, F. Hoffmann-La Roche Ltd, Basel, Switzerland).  
244 Nine microliter of master-mix was filled in the glass capillaries and 1  $\mu$ L volume,  
245 containing 25 ng reverse transcribed total RNA, was added as PCR template. Capillaries  
246 were closed, centrifuged, and placed into the rotor. To improve SYBR Green I quantifica-  
247 tion, fluorescence acquisition was performed at an elevated product specific temperature  
248 level (40). It melts the unspecific PCR products at the elevated temperature, e.g., primer  
249 dimers, eliminates the non-specific fluorescence signal and ensures an accurate quantifica-  
250 tion of the desired product. Temperatures for the elevated fluorescence acquisition in the  
251 fourth segment are listed in Table 2.

252

253 Prior to amplification an initial denaturation step (10 min at 95°C) ensured complete  
254 denaturation of the cDNA. Product specific PCR cycle conditions for all receptor subtypes  
255 and the housekeeping genes are summarized in Table 2. After the last amplification cycle,  
256 PCR products were specified in a melting curve analysis to ensure that they were specific  
257 amplification products.

258

259 To verify the specificity of each PCR quantification method the PCR amplicates were  
260 sequenced. For each product, a PCR run with a 25  $\mu$ L reaction volume was performed to  
261 gain sufficient amounts of PCR amplicates. DNA (5  $\mu$ L) was applied on a 4% agarose gel

262

263

264

265 **Table 2.** Product specific LightCycler PCR conditions for amplification and high temperature  
266 fluorescence acquisition (40) melting temperature of bovine 5-HTR subtype PCR products.

267

Product	Denaturation		Primer annealing		Elongation		Fluorescence acquisition		Melting temperature (°C)
	(°C)	(sec)	(°C)	(sec)	(°C)	(sec)	(°C)	(sec)	
5-HTR <sub>1A</sub>	95	15	60	10	72	21	85	3	91
5-HTR <sub>1B</sub>	95	15	61	10	72	24	83	3	90
5-HTR <sub>1D</sub>	95	15	60	10	72	28	78	3	89
5-HTR <sub>1F</sub>	95	15	60	10	72	23	80	3	85
5-HTR <sub>2A</sub>	95	15	60	10	72	25	72	—	88
5-HTR <sub>2B</sub>	95	15	59	10	72	30	78	3	85
5-HTR <sub>2C</sub>	95	15	59	10	72	23	81	3	84
5-HTR <sub>4</sub>	95	15	60	10	72	21	78	3	87
GAPDH <sup>a</sup>	95	15	60	10	72	20	72	—	88
UbC <sup>b</sup>	95	15	60	10	72	30	72	—	88
18S <sup>c</sup>	95	15	60	10	72	30	72	—	88

279

280 <sup>a</sup>Glyceraldehyde-phosphate-dehydrogenase.281 <sup>b</sup>Ubiquitin.282 <sup>c</sup>18S ribosomal RNA gene.

283 to check for the presence of single bands and to confirm that there was enough DNA for  
 284 sequencing. The remaining 20  $\mu$ L of PCR products were purified with the High Pure PCR  
 285 purification kit (Roche Molecular Diagnostics, Rotkreuz, Switzerland) and directly  
 286 sequenced with the Rhodamine dye terminator cycle sequencing kit (Applied Biosystems,  
 287 Foster City, CA) using the appropriate PCR primers. After purification of sequencing  
 288 products by ethanol precipitation, they were run on an ABI 3100 Genetic Analyzer  
 289 (Applied Biosystems, Foster City, CA) at the Institute of Veterinary Bacteriology, Faculty  
 290 of Veterinary Medicine, University of Berne, Switzerland. Sequences were edited and  
 291 proof-read in both directions using Sequencher<sup>TM</sup> (GeneCodes, Ann Arbor, MI). On  
 292 agarose gel electrophoresis all PCR products moved with one single band and showed the  
 293 expected size. Furthermore, melting temperatures that were performed by the LightCycler  
 294 in a melting curve analysis program after the last amplification cycle demonstrated specific  
 295 PCR products.

296 Ubiquitin (UbC), glyceraldehyde-phosphate-dehydrogenase (GAPDH), and 18S ribo-  
 297 somal RNA gene (18S) were chosen to confirm constant housekeeping gene expression  
 298 levels in the investigated cDNA samples. Mean values  $\pm$  SD of crossing point (CP) values  
 299 of brain, abomasum, and intestine pools for UbC, GAPDH, and 18S are shown in Table 3.  
 300 Spearman correlations between the CPs of the 3 different housekeeping genes calculated  
 301 for each tissue pool are shown in Table 4.

302

303

304

### Mathematical Evaluations and Statistical Analyses

305

306

307

308

309

310

311

312

313

314

315

316

317

318

Expression of mRNA was evaluated by amplification curve analysis of the Light-  
 Cycler real-time RT-PCR. SYBR Green I (DNA binding dye) incorporated into double  
 stranded DNA (dsDNA) emits fluorescence of increasing intensity with cycle number,  
 reflecting target amplification. The exponential growth phase of the PCR begins when the  
 fluorescence signal from accumulated PCR product is greater than the background  
 fluorescence. To eliminate non-informative fluorescence background points, a fluorescence  
 threshold is set to the exponential portion of the amplification curve as low as possible  
 without including any background points. The intersection of the threshold line and  
 the amplification curve represents the CP value (41). Crossing points for each receptor  
 subtype were determined using the second derivate maximum method (41).

319

**Table 3.** Means  $\pm$  SD of housekeeping genes in CPs.

320

321

322

323

324

325

326

327

328

329

	GAPDH <sup>a</sup> (CP)	UbC <sup>b</sup> (CP)	18S <sup>c</sup> (CP)
CNS <sup>d</sup>	20.55 $\pm$ 0.70	20.61 $\pm$ 0.57	15.71 $\pm$ 0.63
Abomasum <sup>e</sup>	19.61 $\pm$ 0.27	19.71 $\pm$ 0.30	15.04 $\pm$ 0.38
Intestine <sup>f</sup>	20.40 $\pm$ 0.26	19.18 $\pm$ 0.29	15.83 $\pm$ 0.71

<sup>a</sup>Glyceraldehyde phosphate dehydrogenase.

<sup>b</sup>Ubiquitin.

<sup>c</sup>18S ribosomal RNA gene.

<sup>d</sup>Central nervous system: thalamus, hypothalamus, cortex (lobus piriformis).

<sup>e</sup>Abomasum: fundus, corpus, antrum.

<sup>f</sup>Intestine: ileum, caecum, PLAC, spiral colon.

**Table 4.** Correlations among housekeeping genes (expression ratio or CP) within tissues.

	GAPDH <sup>d</sup>	UBQ <sup>e</sup>	18S <sup>f</sup>
<b>CNS<sup>a</sup></b>			
GAPDH	1	0.67*	0.36
UBQ		1	0.79*
18S			1
<b>Abomasum<sup>b</sup></b>			
GAPDH	1	0.65*	0.44
UBQ		1	0.46
18S			1
<b>Intestine<sup>c</sup></b>			
GAPDH	1	0.70*	0.54
UBQ		1	0.57
18S			1

\* $P \leq 0.05$ .<sup>a</sup>Central nervous system: thalamus, hypothalamus, cortex (lobus piriformis).<sup>b</sup>Abomasum: fundus, corpus, antrum.<sup>c</sup>Intestine: ileum, caecum, PLAC, spiral colon.<sup>d</sup>Glyceraldehyde phosphate dehydrogenase.<sup>e</sup>Ubiquitin.<sup>f</sup>18S ribosomal RNA gene.

The amount of target gene cDNA was determined using a relative quantification method, i.e., housekeeping gene expression of each sample was used for normalization of 5-HTR expression. The low SD-values of housekeeping gene CP (Table 3) revealed that variation of housekeeping gene expression was generally small and indicated that housekeeping genes were barely regulated. Moreover, in every tissue pool, GAPDH and UbC expression were highly and significantly correlated with each other. Based on that, these two housekeeping genes were considered to be most eligible for normalization of target gene expression. Because GAPDH was used for tissue mapping of human 5-HTR mRNA expression (36), we decided to use GAPDH for normalization in this study also.

According to Medhurst et al. (36) and Inderwies et al. (38), an optimum efficiency ( $e$ ) of PCR ( $e = 2$ ) was assumed for calculation of mRNA expression, where the PCR product is duplicated in every cycle. The 5-HTR mRNA expression was indicated in percentage of GAPDH mRNA expression and was calculated as

$$\frac{1}{2^{(CP[5HTR]-CP[GAPDH])}} \times 100\%$$

For statistical analyses the S-PLUS 6.0 professional program package was used (MathSoft Inc., Seattle, WA). Data are presented as means  $\pm$  SD and the level of significance was set at  $P \leq 0.05$ . Descriptive analysis revealed that values of 5-HTR expression normalized to



377 GAPDH were not derived from a normally distributed population. Therefore, 5-HTR  
378 expression traits were logarithmically transformed in order to fulfill assumptions of  
379 normality. Differences of receptor expression among tissue pools (brain, abomasum,  
380 intestine) within receptor subtype and differences of receptor expression among receptor  
381 subtypes within tissue pools were localized using two-way analysis of variance (ANOVA).  
382 Follow-up tests (paired *t*-tests) were used for pairwise comparison of 5-HTR mRNA  
383 expression within receptor subtypes as well as within tissue pools. Holm corrections (42)  
384 were used for adjustment to repeated testing.

385

386

387

## 388 RESULTS

389

### 390 Primer and PCR-Product Specificity

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

### 416 Bovine 5-HTR Sequences

417

418

419

420

421

422

423

All eight 5-HTR subtypes were previously not described as bovine nucleotide sequences. The partial CDS of the eight bovine 5-HTR subtypes described in this study can be downloaded at (<http://www.ncbi.nlm.nih.gov/Entrez/index.html>). The accession numbers are: **5-HTR<sub>1A</sub>**: *AJ491858*, **5-HTR<sub>1B</sub>**: *AJ491859*, **5-HTR<sub>1D</sub>**: *AJ491860*, **5-HTR<sub>1F</sub>**: *AJ491862*, **5-HTR<sub>2A</sub>**: *AJ491863*, **5-HTR<sub>2B</sub>**: *AJ491864*, **5-HTR<sub>2C</sub>**: *AJ491865*, **5-HTR<sub>4</sub>**: *AJ491866*. The nucleotide sequences as well as the amino acid sequences were highly homologous to the known human, rat, and mouse sequences (Tables 5 and 6). Coding sequence alignment of the bovine partial CDS to human, rat, and mouse complete sequences

**Table 5.** Identity (%) of bovine 5-HTR partial CDS to human, murine, and rat 5-HTR complete CDS.

Receptor	Bovine partial CDS		Human complete CDS		Murine complete CDS		Rat complete CDS	
	NCBI ac. no. <sup>a</sup>	Identity	NCBI ac. no. <sup>a</sup>	Identity	NCBI ac. no. <sup>a</sup>	Identity	NCBI ac. no. <sup>a</sup>	Identity
5-HTR <sub>1A</sub>	AJ491858	91.5	XM_003692	88.2	NM_008308	86.7	NM_012585	86.7
5-HTR <sub>1B</sub>	AJ491859	94.2	XM_004117	91.1	M85151	90.7	NM_022225	90.7
5-HTR <sub>1D</sub>	AJ491860	89.1	NM_000864	86.9	NM_008309	86.9	NM_012852	86.9
5-HTR <sub>1F</sub>	AJ491862	93.5	NM_000866	86.7	NM_008310	—	—	—
5-HTR <sub>2A</sub>	AJ491863	92.9	NM_000621	—	—	89.8	NM_017254	89.8
5-HTR <sub>2B</sub>	AJ491864	91.0	XM_048724	84.7	AJ012488	84.4	NM_017250	84.4
5-HTR <sub>2C</sub>	AJ491865	96.0	NM_000868	93.6	NM_008312	91.1	NM_012765	91.1
5-HTR <sub>4</sub>	AJ491866	93.2	XM_052171	92.7	NM_008313	91.4	NM_012853	91.4

<sup>a</sup>National Center for Biotechnology Information accession number. Web address: <http://www.ncbi.nlm.nih.gov/entrez/index.html>.

424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470

471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517

**Table 6.** Identity (%) of bovine 5-HTR partial amino acid sequences to complete human, murine, and rat 5-HTR amino acid sequences.

Receptor	Bovine partial CDS		Human complete CDS		Murine complete CDS		Rat complete CDS	
	NCBI ac. no. <sup>a</sup>	Identity	NCBI ac. no. <sup>a</sup>	Identity	NCBI ac. no. <sup>a</sup>	Identity	NCBI ac. no. <sup>a</sup>	Identity
5-HTR <sub>1A</sub>	AJ491858	97.1	XM_003692	97.1	NM_008308	97.1	NM_012585	97.1
5-HTR <sub>1B</sub>	AJ491859	97.6	XM_004117	97.6	M85151	97.6	NM_022225	97.6
5-HTR <sub>1D</sub>	AJ491860	88.2	NM_000864	88.2	NM_008309	87.9	NM_012852	88.8
5-HTR <sub>1F</sub>	AJ491862	98.8	NM_000866	98.8	NM_008310	93.9	—	—
5-HTR <sub>2A</sub>	AJ491863	99.1	NM_000621	99.1	—	—	NM_017254	98.1
5-HTR <sub>2B</sub>	AJ491864	91.2	XM_048724	91.2	AJ012488	80.3	NM_017250	77.4
5-HTR <sub>2C</sub>	AJ491865	96.4	NM_000868	96.4	NM_008312	100.0	NM_012765	96.4
5-HTR <sub>4</sub>	AJ491866	91.8	XM_052171	91.8	NM_008313	93.2	NM_012853	89.0

<sup>a</sup>National Center for Biotechnology Information accession number. Web address: <http://www.ncbi.nlm.nih.gov/entrez/index.html>.

518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531

**Table 7.** Coefficients of variation of real-time RT-PCR methods for bovine 5-HTR mRNA determination.

Receptor	Intra-assay CV (%)	Inter-assay CV (%)
5-HTR <sub>1A</sub>	0.54	0.64
5-HTR <sub>1B</sub>	0.52	1.55
5-HTR <sub>1D</sub>	1.83	0.84
5-HTR <sub>1F</sub>	1.07	0.98
5-HTR <sub>2A</sub>	0.86	1.19
5-HTR <sub>2B</sub>	2.46	1.03
5-HTR <sub>2C</sub>	0.51	0.58
5-HTR <sub>4</sub>	0.66	0.49

532  
533  
534  
535

revealed that the bovine sequences matched the human, mouse, and rat sequences exactly in the regions where the primer have been designed.

536  
537  
538  
539  
540  
541  
542  
543  
544

#### Distribution of mRNA Expression

Expression levels of the various receptor subtypes are shown in Figs. 1 and 2. There was a high variation of 5-HTR subtype mRNA expression within tissue among receptor subtypes, as well as within receptor subtypes among tissues. Except for 5-HTR<sub>1A</sub> in abomasum and intestine and 5-HTR<sub>2C</sub> in abomasum, every established bovine 5-HTR subtype could be detected in every tissue pool.

545  
546


#### DISCUSSION

547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564

In this study, assays for quantitative analysis of bovine 5-HTR mRNA expression were developed and described for the first time. Primer design and optimization was done in the high homology regions of the multiple alignments of published human, mouse, and rat sequences and quantification was done relative to the housekeeping gene GAPDH using the LightCycler SYBR Green I technology. Methods for the determination of eight (5-HTR<sub>1A</sub>, 5-HTR<sub>1B</sub>, 5-HTR<sub>1D</sub>, 5-HTR<sub>1F</sub>, 5-HTR<sub>2A</sub>, 5-HTR<sub>2B</sub>, 5-HTR<sub>2C</sub>, and 5-HTR<sub>4</sub>) of 14 known 5-HT R subtypes could be developed in the bovine species.

The specificities of the amplified nucleotide products were confirmed by agarose gel electrophoresis of the product yielding single bands, melting curve analysis, and sequencing of the product.

The eight new bovine partial CDS were compared with the known human, mouse, and rat complete CDS. Because partial CDS were compared with complete CDS, this comparison of CDS across species might have been biased. Therefore, these results have to be carefully interpreted. Nevertheless, high homologies between the bovine and the human, mouse, and rat sequences were to be expected, because 5-HTR have been highly conserved throughout evolution, as evidenced by molecular cloning (5). Typically, the CDS identity was higher between bovine and human than between bovine and mouse or rat. Due to triplet code redundancy, the homologies of amino acid sequences between



**Figure 1.** The 5-HTR mRNA expression level in bovine tissues relative to GAPDH mRNA expression grouped by receptor subtype. Values are means  $\pm$  SD. *Key:* \*5-HTR mRNA expression is significantly different within receptor subtype ( $P < 0.05$ ); a–c: significant differences ( $P < 0.05$ ) between two tissues within receptor; d and e: significant differences ( $P < 0.1$ ) between two tissues within receptor; (1) 5-HTR<sub>1A</sub> mRNA not detectable in abomasum and intestine. (2) 5-HTR<sub>2C</sub> mRNA not detectable in abomasum.

bovine and human, mouse, and rat were generally even higher than the homologies between nucleotide sequences.


Validation of the eight newly developed assays for quantitative mRNA analysis of bovine 5-HTRs by calculation of intra- and inter-assay CVs revealed that the repeatability of the measurements and the accuracy of the assays were high.

Analysis of housekeeping gene CPs of each sample revealed that GAPDH and UbC were most suitable for normalization of 5-HTR expression. Because GAPDH was used for tissue mapping of human 5-HTR mRNA expression (36), we decided to use GAPDH for normalization in this study also.

The CPs of bovine 5-HTR mRNA analysis were rather high, i.e., expression levels of bovine 5-HTR were rather low and accounted for 0.001% to 1% of GAPDH expression only. However, considering that signaling by serotonin binding to 5-HTR is strongly amplified by second messengers, this fact is not surprising (8).

Expression levels of bovine 5-HTR were comparable to expression levels of human 5-HTR. Thus, expression levels for 5-HTR<sub>4</sub> were 0.05% and 0.7% 5-HTR<sub>4</sub>/GAPDH in human whole brain and small intestine (36) and 0.04% and 0.8% 5-HTR<sub>4</sub>/GAPDH in bovine brain and intestine pool, respectively.

Interestingly, 5-HTR expression varied considerably among tissues within receptor subtype as well as among receptor subtypes within tissues. Moreover, the tissue with highest 5-HTR mRNA expression levels varied from subtype to subtype, suggesting different effects of 5-HT stimulations within tissues.



**Figure 2.** The 5-HTR mRNA expression level in bovine tissues relative to GAPDH mRNA expression grouped by tissue. Values are means  $\pm$  SD. Key: \*5-HTR mRNA expression is significantly different within tissue ( $P < 0.001$ ); a–d: significant differences ( $P < 0.05$ ) between two receptors within tissue R. (1) 5-HTR<sub>1A</sub> mRNA not detectable in abomasum and intestine. (2) 5-HTR<sub>2C</sub> mRNA not detectable in abomasum.

In conclusion, this study demonstrates development and validation of assays for quantitative mRNA analysis of eight bovine 5-HTR subtypes. A first physiological application shows a variable and an obviously tissue-specific distribution of these subtypes in bovine brain, abomasum, and intestine tissue pools. Because the bovine 5-HTR nucleotide sequences were completely unknown before, primers used for bovine cDNA amplification were either derived from human or mouse complete CDS in highly homologous regions across species (human, mouse, and rat). In future, the real-time RT-PCR assays developed in this study will allow for detailed mapping of the bovine tissues with respect to 5-HTR subtype expression. Furthermore, the determination of 5-HTR subtype expression represents an additional tool in research on bovine production diseases such as disorders of GI motility (displaced abomasum, cecal dilatation/displacement) and uterus motility in cattle and completes existing techniques such as measurement of muscular contractions upon specific 5-HTR stimulation in vitro or electromyographical recordings in vivo. However, we have to keep in mind that mRNA determination is not a physiological measure, especially if it is based on partial sequences.

#### ACKNOWLEDGMENTS

The excellent technical assistance by Mrs. D. Schmidt is gratefully acknowledged. We thank PD Dr. P. Kuhnert, Institute of Veterinary Bacteriology, University of Berne, Switzerland, for sequencing the PCR products. We also thank the staff of the slaughterhouse of Berne, Switzerland, for the support in tissue sample collection. Prof. Dr. A. Zurbriggen and Dr. R. Meyer, Institute of Animal Neurology, University of Berne,

659 Switzerland, provided the facilities for dissection and processing of bovine brain tissue for  
660 which we are very grateful.

661

662

663

664

## REFERENCES

- 665 1. Zifa E, Fillion G. 5-Hydroxytryptamine receptors. *Pharmacol Rev* 1992; 44(3):401–458.
- 666 2. Roth BL. Multiple serotonin receptors: clinical and experimental aspects. *Ann Clin*  
667 *Psychiatry* 1994; 6(2):67–78.
- 668 3. Barnes NM, Sharp T. A review of central 5-HT receptors and their function.  
669 *Neuropharmacology* 1999; 38(8):1083–1152.
- 670 4. Taniyama K, Makimoto N, Furuichi A, Sakurai-Yamashita Y, Nagase Y, Kaibara M,  
671 Kanematsu T. Functions of peripheral 5-hydroxytryptamine receptors, especially  
672 5-hydroxytryptamine<sub>4</sub> receptor, in gastrointestinal motility. *J Gastroenterol* 2000;  
673 35(8):575–582.
- 674 5. Peroutka SJ. Molecular biology of serotonin (5-HT) receptors. *Synapse* 1994;  
675 18(3):241–260.
- 676 6. Briejer MR, Akkermans LM, Schuurkes JA. Interactions of serotonin with multiple  
677 receptors and neurotransmitters in guinea-pig isolated colon. *Arch Int Pharmacodyn*  
678 *Ther* 1995; 329(1):121–133.
- 679 7. Hedge SS, Moy TM, Perry MR, Loeb M, Eglen RM. Evidence for the involvement  
680 of 5-hydroxytryptamine 4 receptors in 5-hydroxytryptophan-induced diarrhea in mice.  
681 *J Pharmacol Exp Ther* 1994; 271(2):741–747.
- 682 8. Pauwels PJ. Diverse signaling by 5-hydroxytryptamine (5-HT) receptors. *Biochem*  
683 *Pharmacol* 2000; 60(12):1743–1750.
- 684 9. Hansen M. Serotonin—an intestinal secretagogue—receptor subtypes and intracellu-  
685 lar mediators. *Pharmacol Toxicol* 1995; 77(Suppl 1):3–39.
- 686 10. Bartlett PC, Kopcha M, Coe PH, Ames NK, Ruegg PL, Erskine RJ. Economic  
687 comparison of the pyloro-omentopexy vs the roll-and-toggle procedure for the  
688 treatment of left displacement of the abomasum in dairy cattle. *J Am Vet Med*  
689 *Assoc* 1995; 206(8):1156–1162.
- 690 11. Eicher R, Audigé L, Braun U, Blum J, Meylan M, Steiner A. Epidemiologie und  
691 Risikofaktoren der Blinddarmdilatation und Labmagenverlagerung bei der Milchkuh.  
692 *Schweiz Arch Tierheilk* 1999; 141(9):423–429.
- 693 12. Gershon MD, Wade PR, Kirchgessner AL, Tamir H. 5-HT receptor subtypes outside  
694 the central nervous system. Roles in the physiology of the gut. *Neuropsychopharma-*  
695 *cology* 1990; 3(5–6):385–395.
- 696 13. Kadowaki M, Nagakura Y, Tomoi M, Mori J, Kohsaka M. Effect of FK1052, a potent  
697 5-hydroxytryptamine<sub>3</sub> and 5-hydroxytryptamine<sub>4</sub> receptor dual antagonist, on colonic  
698 function in vivo. *J Pharmacol Exp Ther* 1993; 266(1):74–80.
- 699 14. Olsson C, Holmgren S. The control of gut motility. *Comp Biochem Physiol A Mol*  
700 *Integr Physiol* 2001; 128(3):481–503.
- 701 15. Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the  
702 modulation of gastrointestinal motility and sensation: clinical implications. *Aliment*  
703 *Pharmacol Ther* 1992; 6(3):273–289.
- 704 16. Dhasmana KM, Zhu YN, Cruz SL, Villalon CM. Gastrointestinal effects of 5-  
705 hydroxytryptamine and related drugs. *Life Sci* 1993; 53(22):1651–1661.

- 706 17. Plaza MA, Arruebo MP, Murillo MD. Evidence for the involvement of 5-HT<sub>4</sub>  
707 receptors in the 5-hydroxytryptamine-induced pattern of migrating myoelectric com-  
708 plex in sheep. *Br J Pharmacol* 1997; 120(6):1144–1150.
- 709 18. Humphrey PP, Bountra C, Clayton N, Kozlowski K. Review article: the therapeutic  
710 potential of 5-HT<sub>3</sub> receptor antagonists in the treatment of irritable bowel syndrome.  
711 *Aliment Pharmacol Ther* 1999; 13(Suppl 2):31–38.
- 712 19. Plaza MA, Arruebo MP, Murillo MD. Effects of 5-hydroxytryptamine agonists on  
713 myoelectric activity of the forestomach and antroduodenal area in sheep. *J Pharm*  
714 *Pharmacol* 1996; 48(12):1302–1308.
- 715 20. Brikas P, Kania BF, Fioramonti J, Bueno L. Central and peripheral serotonergic  
716 influences on viscerovisceral inhibitory reflex during duodenal distension in sheep.  
717 *Dig Dis Sci* 1993; 38(6):1079–1086.
- 718 21. Plaza MA, Arruebo MP, Murillo MD. 5-Hydroxytryptamine induces fore-  
719 stomach hypomotility in sheep through 5-HT<sub>4</sub> receptors. *Exp Physiol* 1996;  
720 81(5):781–790.
- 721 22. Appel-Dingemans S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT<sub>4</sub>(4)  
722 receptor partial agonist with promotile activity. *Clin Pharmacokinet* 2002;  
723 41(13):1021–1042.
- 724 23. Banner SE, Smith MI, Bywater D, Gaster LM, Sanger GJ. Increased defaecation  
725 caused by 5-HT<sub>4</sub> receptor activation in the mouse. *Eur J Pharmacol* 1996;  
726 308(2):181–186.
- 727 24. Borman RA, Burleigh DE. Human colonic mucosa possesses a mixed population of  
728 5-HT receptors. *Eur J Pharmacol* 1996; 309(3):271–274.
- 729 25. Prins NH, Briejer MR, Schuurkes JA. Characterization of the contraction to 5-HT  
730 in the canine colon longitudinal muscle. *Br J Pharmacol* 1997; 120(4):714–720.
- 731 26. Ruckebusch Y. Pharmacology of reticulo-ruminal motor function. *J Vet Pharmacol*  
732 *Ther* 1983; 6(4):245–272.
- 733 27. Ruckebusch Y, Bardon T. Involvement of serotonergic mechanisms in initiation of  
734 small intestine cyclic motor events. *Dig Dis Sci* 1984; 29(6):520–527.
- 735 28. Ruckebusch Y. Enhancement of the cyclic motor activity of the ovine small intestine  
736 by lysergic acid derivatives. Mechanism and significance. *Gastroenterology* 1984;  
737 87(5):1049–1055.
- 738 29. Sorraing JM, Fioramonti J, Bueno L. Effects of dopamine and serotonin on eructation  
739 rate and ruminal motility in sheep. *Am J Vet Res* 1984; 45(5):942–947.
- 740 30. Sorraing JM, Fioramonti J, Bueno L. Central and peripheral serotonergic control of  
741 forestomach motility in sheep. *J Vet Pharmacol Ther* 1985; 8(3):312–319.
- 742 31. Veenendaal GH, Woutersen-van Nijnanten FM, van Miert AS. Responses of goat  
743 ruminal musculature to bradykinin and serotonin in vitro and in vivo. *Am J Vet Res*  
744 1980; 41(4):479–483.
- 745 32. Brikas P, Fioramonti J, Bueno L. Types of serotonergic receptors involved in the  
746 control of reticulo-ruminal myoelectric activity in sheep. *J Vet Pharmacol Ther* 1994;  
747 17(5):345–352.
- 748 33. Brikas P. Motor-modifying properties of 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptor agonists on ovine  
749 abomasum. *J Vet Med A* 1994; 41(2):150–158.
- 750 34. Kitamura N, Yamada J, Calingasan NY, Yamashita T. Histologic and immunocyto-  
751 chemical study of endocrine cells in the gastrointestinal tract of the cow and calf.  
752 *Am J Vet Res* 1985; 46(6):1381–1386.



- 753 35. Medhurst AD, Harrison DC, Read SJ, Campbell CA, Robbins MJ, Pangalos MN. The  
754 use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in  
755 CNS tissues and disease models. *J Neurosci Methods* 2000; 98(1):9–20.
- 756 36. Medhurst AD, Lezoualc'h F, Fischmeister R, Middlemiss DN, Sanger GJ. Quantitative  
757 mRNA analysis of five C-terminal splice variants of the human 5-HT<sub>4</sub> receptor in the  
758 central nervous system by TaqMan real time RT-PCR. *Brain Res Mol Brain Res* 2001;  
759 90(2):125–134.
- 760 37. Paffl MW, Mircheva Georgieva T, Penchev Georgiev I, Ontsouka E, Hageleit M,  
761 Blum JW. Real-time RT-PCR quantification of insulin-like growth factor (IGF)-1,  
762 IGF-1 receptor, IGF-2 receptor, insulin receptor, growth hormone receptor,  
763 IGF-binding proteins 1, 2, and 3 in the bovine species. *Domest Anim Endocrinol*  
764 2002; 22(2):91–102.
- 765 38. Inderwies T, Pfaffl MW, Meyer HH, Blum JW, Bruckmaier RM. Detection and  
766 quantification of mRNA expression of alpha- and beta-adrenergic receptor subtypes in  
767 the mammary gland of dairy cows. *Domest Anim Endocrinol* 2003; 24(2):123–135.
- 768 39. Brandstetter AM, Pfaffl MW, Hocquette JF, Gerrard DE, Picard B, Geay Y,  
769 Sauerwein H. Effects of muscle type, castration, age, and compensatory growth rate  
770 on androgen receptor mRNA expression in bovine skeletal muscle. *J Anim Sci* 2000;  
771 78(3):629–637.
- 772 40. Pfaffl MW, Hageleit M. Validities of mRNA quantification using recombinant RNA  
773 and recombinant DNA external calibration curves in real-time RT-PCR. *Biotechnol*  
774 *Lett* 2001; 23(4):275–282.
- 775 41.  
776 eds. *Rapid Cycle Real-Time PCR, Methods and Applications*. Heidelberg (Germany):  
777 Springer, 2001:21–34.
- 778 42. Holm S. A simple sequentially rejective multiple test procedure. *Scand J Stat* 1979;  
779 6:65–70.
- 780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799